Darcy Burbage, Oncology Clinical Nurse Specialist, shared on X:
”In summary, benefits of early MRD detection/intervention remain uncertain and prospective ctDNA-guided intervention studies are needed.
Tissue-Free vs Tumor-Informed ctDNA Assays in Early Triple Negative BrCa.”
Title: Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer
Authors: Niamh Cunningham, Rosalind J. Cutts, Claire Swift, Maria Coakley, Prithika Sritharan, Kathryn Dunne, Monisha Dewan, Lucy Kilburn, Katie Goddard, Peter Hall, Catherine Harper-Wynne, Iain R. Macpherson, Alicia Okines, Andrew Wardley, Simon Waters, Carlo Palmieri, Matthew Winter, Judith Bliss, Isaac Garcia-Murillas, Nicholas C. Turner
Other articles about ctDNA on OncoDaily.